Yeji
FDA approvalconf 0.98

zilretta — FDA approval

$PCRX · Pacira BioSciences, Inc. · Management of osteoarthritis (OA)-related knee pain
Event date
October 6, 2017
3165 days ago
Sponsor runway
cash-flow +
$202.2M liquid

Evidence

“On October 6, 2017, ZILRETTA (triamcinolone acetonide extended-release injectable suspension) was approved by the U.S. Food and Drug Administration as the first and only extended-release intra-articular therapy for patients confronting osteoarthritis (OA)- related knee pain.”
Source: Press release · 2021-11-19View press release ↗

Comparable historical fda approvals· last 5 years · same event type

100% hit rate (10/10)
TickerDrugDateOutcome
$INCYzynyz2026-05-18success
$INCYjakafi xr2026-05-01success
$AXSMauvelity2026-04-30success
$INCYzynyz2026-03-30success
$BIIBspinraza2026-03-27success
$CORTlifyorli2026-03-25success
$RYTMimcivree2026-03-19success
$ASNDyuviwel2026-02-27success
$BMRNpalynziq2026-02-27success
$ETONdesmoda2026-02-25success

Recent insider activity· ±90 days

No insider Form 4 activity reported on $PCRX in the 90 days around this event.
← All catalysts for $PCRX